Senhwa Biosciences Company Description

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents.

The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer.

It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma.

In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19.

Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.

Senhwa Biosciences, Inc.

Country	Taiwan
Founded	2012
Industry	Biotechnology
Sector	Healthcare
CEO	Jason Huang

Contact Details

Address: No. 225, Peihsin Road New Taipei City, 23143 Taiwan
Phone	886 2 8911 9856
Website	senhwabio.com

Stock Details

Ticker Symbol	6492
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006492002
SIC Code	2836

Key Executives

Name	Position
Jason Huang	Chief Executive Officer
Sarah Chang	Chief Financial Officer
Joanne Lo	Chief Operating Officer